BUENA, N.J., April 08, 2020 -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the fourth.

BUENA, N.J., Nov. 04, 2019 -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third.

Q4 2019 Teligent Inc (NEW JERSEY) Earnings Call

Long term investing works well, but it doesn't always work for each individual stock. It hits us in the gut when we...

A South Jersey specialty generic pharmaceutical company has made a leadership change. Teligent Inc. (NASDAQ: TLGT) announced Wednesday that Jason Grenfell-Gardner has stepped down, effective immediately, as president and CEO and as a member of the company's board of directors. Grenfell-Gardner had been with the company for more than seven years.

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 23) 10X Genomics Inc (NASDAQ: TXG )(reacted to a ruling ...

BUENA, N.J., April 03, 2020 -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00.

A South Jersey specialty generic pharmaceutical company encountered a setback this week with its efforts to get regulatory approval for its first complex drug targeting an orphan disease population. Teligent of Buena in Atlantic County said its development partner, an unidentified contract research organization, received a letter from the Food and Drug Administration in which the federal agency requested further information and raw data to support the filing of an abbreviated new drug application (ANDA) for the Teligent product.

BUENA, N.J., May 19, 2020 -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, announced they will hold a conference call at 8:00AM ET.

Teligent has announced that Jason Grenfell-Gardner will be stepping down immediately as President, CEO and member of the Board of Directors. Mr. Grenfell-Gardner and the Board of Directors have mutually agreed that now is the right time to transition the leadership of the Company.

NEW YORK, NY / ACCESSWIRE / May 22, 2020 / Teligent, Inc. (NASDAQ:TLGT) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on May 22, 2020 at 8:00 AM Eastern ...

Shares of Teligent (NASDAQ:TLGT) rose 11% in pre-market trading after the company reported Q4 results.Quarterly Results Earnings per share rose 5.56% year over year to ($0.17), which missed the estimate of ($0.02).Revenue of $15,967,000 lower by 4.83% year over year, which missed the estimate of $19,510,000.Looking Ahead Teligent hasn't issued any earnings guidance for the time being.Teligent hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Apr 08, 2020View more earnings on TLGTTime: 08:05 AM ETWebcast URL: https://edge.media-server.com/mmc/p/wv4e8pvdTechnicals 52-week high: $1.1352-week low: $0.19Price action over last quarter: down 47.57%Company Profile Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.See more from Benzinga * 11 Industrials Stocks Moving In Wednesday's Pre-Market Session * Recap: Northern Technologies Q2 Earnings * Recap: AngioDynamics Q3 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

At a Special Meeting of Stockholders held on January 24, 2020 the reverse stock split was approved by the Company's stockholders to be effected at the Board’s discretion within the approved parameters and the specific ratio was subsequently approved by the Company's Board. The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market although no assurance can be given that continued listing will occur.

Teligent, Inc. (TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for its first complex drug indicated for an orphan disease population. In the letter, the FDA requested further information and raw data to support the ANDA.

BUENA, N.J., May 22, 2020 -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first.

Shares of Teligent (NASDAQ:TLGT) moved higher by 34% in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share were down 155.56% year over year to ($0.23), which missed the estimate of ($0.18).Revenue of $7,447,000 decreased by 43.25% year over year, which missed the estimate of $7,950,000.Outlook Earnings guidance hasn't been issued by the company for now.View more earnings on TLGTTeligent hasn't issued any revenue guidance for the time being.Technicals 52-week high: $1.09Company's 52-week low was at $0.19Price action over last quarter: Up 62.92%Company Description Teligent Inc is a specialty generic pharmaceutical company. Teligent develops, manufactures, and sells (under its own label) topical, injectable, complex, and ophthalmic pharmaceutical products in the U.S. and Canada. The product portfolio consists of hospital-based sterile injectable products and topical products (creams like Synalar and Spectazole; lotions like Kenalog; ointments like Topicort and Kenalog; and topical solutions like Pennsaid and Xylocaine). The company also offers services to the pharmaceutical, over-the-counter, and cosmetic markets.See more from Benzinga * Afternoon Market Stats in 5 Minutes * Recap: Teligent Q4 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]

Q3 2019 Teligent Inc Earnings Call

Teligent (TLGT) delivered earnings and revenue surprises of -100.00% and -6.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

BUENA, N.J., Nov. 13, 2019 -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Jefferies Global Healthcare.